Cyclosporine for moderate-to-severe alopecia areata: A double-blind, randomized, placebo-controlled clinical trial of efficacy and safety - 15/08/19
, Gang Chen, PhD, MMSc, BMed b, Douglas Gin, MBBS, FACD c, Rodney Sinclair, MBBS, MD, FACD dAbstract |
Background |
Despite widespread use of steroid-sparing agents, particularly cyclosporine, for treatment of alopecia areata (AA), there are no clinical trials investigating the efficacy of these agents.
Objective |
To evaluate the efficacy of cyclosporine compared with placebo at 3 months in patients aged 18 to 65 years with moderate-to-severe AA.
Methods |
A double-blind, randomized, placebo-controlled trial was conducted. Adults aged 18 to 65 years of age with moderate-to-severe AA were randomized in a 1:1 ratio to receive 3 months of cyclosporine (4 mg/kg/d) or matching placebo. Blinded assessments included physical examination, blood biochemistry, photography, quality of life measurements, and efficacy evaluation using Severity of Alopecia Tool score and eyelash and eyebrow assessment scales.
Results |
The results obtained for 32 participants (16 who received cyclosporine and 16 who received placebo) were analyzed. Compared with the placebo group, the cyclosporine group had a greater proportion of participants achieving at least a 50% reduction in Severity of Alopecia Tool score (31.3% vs 6.3% [P = .07]) and greater proportion of participants achieving a 1-grade improvement in eyelash (18.8% vs 0% [P = .07]) and eyebrow (31.3% vs 0% [P = .02]) scale score.
Limitations |
Small sample size and single-institution trial may limit interpretation and generalizability of these results.
Conclusion |
Response approached but did not reach a statistically significant difference between cyclosporine and placebo.
Le texte complet de cet article est disponible en PDF.Key words : alopecia, alopecia areata, clinical trial, cyclosporine, immunosuppressive agents, randomized controlled trial
Abbreviations used : AA, AT, AU, QOL, SALT
Plan
| Funding sources: Supported by the Australia Alopecia Areata Foundation. |
|
| Conflicts of interest: None disclosed. |
|
| Reprints not available from the authors. |
Vol 81 - N° 3
P. 694-701 - septembre 2019 Retour au numéro
Article précédent
- Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients
- Hui Kai Koh, Zi Teng Chai, Hui Wen Tay, Stephanie Fook-Chong, Karen J.L. Choo, Choon Chiat Oh, Yi Wei Yeo, Hong Yi Koh, Shiu Ming Pang, Haur Yueh Lee
- Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa
- Ashley N. Oskardmay, J. Alex Miles, Christopher J. Sayed
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?